Leerink Partners Downgrades Bristol-Myers Squibb to Market Perform, Lowers Price Target to $59

Benzinga Newsdesk www.benzinga.com Negative 91.3%

Neg 91.3% Neu 0% Pos 0%

Leerink Partners analyst David Risinger downgrades Bristol-Myers Squibb (NYSE:BMY) from Outperform to Market Perform and lowers the price target from $73 to $59.